Macrogenics Inc

+0.36 (+1.44%)
Products, Strategic Combinations

MacroGenics And Zai Lab Enter Into Broad Strategic Collaboration

Published: 06/16/2021 11:54 GMT
Macrogenics Inc (MGNX) - Macrogenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology.
Macrogenics Inc - Zai Lab Granted Combination of Regional Asian and Global Rights for Up to Four Cd3- Or Cd47-based Bispecific Molecules.
Macrogenics - Provides Rights to Zai Lab for Its Dart and Trident Multi-specific Platforms and a Lead Research Program Targeting Solid Tumors.
Macrogenics Inc - Zai Lab Provides Rights to Macrogenics for Certain Intellectual Property Related to Cd47 for Select Tumor Targets.
Macrogenics Inc - Under Terms of Agreement, Macrogenics Receives Initial Consideration From Zai Lab of $55 Million.
Macrogenics - Initial Consideration From Zai Lab Includes Upfront Payment of $25 Million,equity Investment of $30 Million in Co's Common Stock at $31.30/share.
Macrogenics Inc - is Eligible to Receive Up to $1.4 Billion in Potential Development, Regulatory and Commercial Milestone Payments for Four Programs.
Macrogenics - If Products From Collaboration Are Commercialized, Co Would Also Receive Royalties on Annual Net Sales in Zai Lab's Territories.